Successfully Concluded | Tongling Bionic Shines at CMEF 2025

On September 29, the 92nd CMEF (China International Medical Equipment Fair) successfully concluded. During the event, several flagship products from Tongling Bionic were prominently showcased, along with two thematic presentations, attracting widespread attention from domestic and international audiences.

IABP + IAB: A Dual First in China, Showcasing Domestic Innovation Strength

As China's first independently developed Intra-Aortic Balloon Pump (IABP), the Tongling Bionic TL-IABP-100 has undergone years of meticulous refinement and continuous improvement. Equipped with advanced control algorithms and an efficient pneumatic system, it can provide stable hemodynamic support for critically ill cardiac patients, thereby improving treatment success rates.

The Tongling Bionic TL-IAB-30 and TL-IAB-40 also represent China's first independently developed Intra-Aortic Balloon (IAB) catheters. These products utilize high-quality materials, optimized structural design, and intelligent manufacturing processes, delivering excellent overall performance in terms of pushability, kink resistance, and wear resistance. They enable faster inflation and deflation speeds, providing superior hemodynamic support.

TeleVad: Internationally Leading Hemodynamic Assist Technology

Percutaneous ventricular assist technology is currently one of the most popular and advanced circulatory support technologies globally, and Tongling Bionic is among the earliest domestic enterprises to venture into this field. The company's TeleVad, features a range of catheter pumps including models P35, P50, and RP50. It adopts a mature built-in motor design and advanced low-hemolysis technology, continuously enhancing product safety and effectiveness. The product has been selected for the National Key R&D Program and has entered the special review process for innovative medical devices under the National Medical Products Administration.

EECP + NiCOM: Building a Service Model for Prevention, Treatment, and Rehabilitation

The enhanced external counterpulsation device TL-EECP-100 is primarily used for the treatment and rehabilitation of ischemic cardiovascular and cerebrovascular diseases. It offers the advantages of being non-invasive, safe, easy to operate, and comfortable during the procedure. Meanwhile, the non-invasive cardiac output monitor TL-NiCOM-100 utilizes thoracic electrical bioimpedance to monitor hemodynamics. It is equally safe, non-invasive, and provides reliable results, making it suitable for multi-level applications such as early prevention, clinical diagnosis and treatment, and exercise rehabilitation.

Two Keynotes: Talent Advantage & Medical-Engineering Integration

Beyond the product exhibition, Tongling Bionic also conducted two thematic keynote speeches. Feng Qitao, Director of the First R&D Department, delivered a presentation titled "Development of an Percutaneous Right Ventricular Assist Device and the Integration of Medicine and Engineering." He elaborated on the innovative breakthroughs achieved through the deep integration of medical science and engineering technology during the product's development process.

Zhao Dan, Director of the Company's Treatment Program Promotion Department, delivered a presentation centered on the theme "Leveraging the Wisdom of USTC to Forge a 'Chinese Heart' Medical Device." He shared insights into Tongling Bionic's talent advantages, innovative capabilities, and core products, highlighting its status as one of the first equity-holding incubator enterprises spun off from the Advanced Technology Research Institute of the University of Science and Technology of China (USTC).

As the global population ages, the number of heart failure patients continues to rise, creating an urgent need for more comprehensive and accessible solutions. Tongling Bionic is committed to becoming a world-leading provider of integrated, full-lifecycle solutions for heart failure. Through persistent independent innovation, the company has developed multiple product pipelines that cover the entire process of heart failure diagnosis, treatment, and rehabilitation. Looking ahead, we will continue to develop more high-quality innovative medical devices to contribute to public health.